Mechanism of action
Transcutaneous vagus nerve stimulation (tVNS) targets the auricular branch of the vagus nerve (ABVN), also known as Arnold's nerve. The electrode is positioned at the cymba concha of the external ear, a region with 100% vagal innervation density compared to approximately 45% at the tragus.
Afferent signals from the ABVN travel to the nucleus tractus solitarius (NTS) in the medulla. From the NTS, projections extend to multiple downstream targets:
- Locus coeruleus releases norepinephrine, modulating attention, arousal, and neuroplasticity
- Raphe nuclei release serotonin, influencing mood regulation and pain modulation
- Thalamus and salience network engage the insula and anterior cingulate cortex, supporting interoceptive processing and cognitive control
tVNS also engages the cholinergic anti-inflammatory pathway. Vagal efferent activation triggers acetylcholine release in the spleen, which acts on alpha-7 nicotinic receptors on macrophages to suppress production of pro-inflammatory cytokines including TNF-alpha, IL-1, and IL-6. This mechanism is relevant to any condition with a neuroinflammatory component.
Cymba concha targeting
Precise electrode placement is critical to therapeutic outcomes. The cymba concha is the preferred target because it receives exclusively vagal innervation. The tragus, by contrast, has a mixed innervation profile with only approximately 45% vagal fibres.
One further consideration: the ABVN overlaps with the great auricular nerve in 37% of the medial dorsal middle third of the ear. Clinicians should be aware of this anatomical variability when positioning electrodes, as stimulation of non-vagal fibres may reduce the specificity of neural target engagement.
Stimulation parameters
The following table summarises typical stimulation parameters used in clinical research and practice. It is worth noting that parameter standardisation remains an active area of investigation, and protocols vary across studies.
| Parameter | Typical Range | |-----------|--------------| | Frequency | 20 to 30 Hz | | Pulse width | 200 to 500 microseconds | | Amplitude | 0.2 to 5 mA (titrated to sensory threshold) | | Session duration | 1 to 4 hours daily | | Duty cycle | Varies by protocol |
Amplitude is titrated to a "strong sensory but not painful" threshold. This subjective calibration is one of the challenges in achieving consistent dosing across patients and is an area where objective biomarkers of neural target engagement would be valuable.
Clinical evidence by indication
The evidence base for tVNS spans several neurological and psychiatric indications at varying levels of maturity.
| Indication | Key Evidence | Status | |-----------|-------------|--------| | Epilepsy | 30% responder rate at 5 years (comparable to implanted VNS at 32%). NEMOS pilot: 34.2% seizure reduction over 20 weeks | Approved (EU-MDR) | | Depression | Long-term response rates of 67.6%. Modulates salience network connectivity | Approved (EU-MDR) | | Chronic migraine | 50% reduction in migraine days at 12 weeks. gammaCore FDA-cleared for migraine and cluster headache. PREVA trial: 5.9 fewer attacks per week | Approved (EU-MDR) | | Prader-Willi syndrome | 50% reduction in outburst frequency in 80% of patients at 12 months | Approved (EU-MDR) | | Stroke rehabilitation | VNS-REHAB: 88% response rate (6+ FMA-UE points) vs 33% control. Meta-analysis (18 RCTs, 954 patients): SMD 0.89 upper limb, 0.95 Barthel. TRICEPS trial ongoing (15 UK centres, results expected July 2026) | Emerging | | Spinal cord injury | Nature 2025: closed-loop VNS doubled functional improvements vs sham | Emerging |
The stroke rehabilitation evidence is particularly noteworthy. The VNS-REHAB trial demonstrated that pairing tVNS with task-specific upper limb training produced clinically meaningful improvements in 88% of participants, compared with 33% in the control group receiving training alone. The ongoing TRICEPS trial across 15 UK centres will provide further evidence in a real-world NHS setting.
Safety profile and contraindications
tVNS is generally well tolerated, with adverse events that are typically mild and transient.
Common side effects include ear pain at the stimulation site, tingling, skin redness, and local irritation. Headache and dizziness have been reported in approximately 5 to 6% of participants across trials.
Absolute contraindications:
- Active implantable devices (cardiac pacemakers, cochlear implants)
- Pregnancy (insufficient safety data)
- Carotid atherosclerosis (for cervical transcutaneous VNS only)
Relative contraindications:
- Cardiac disease or arrhythmia
- Cerebral shunts
The safety profile compares favourably with implanted VNS, which carries surgical risks including infection and vocal cord paresis. The non-invasive nature of tVNS is one of its principal advantages in a rehabilitation context.
Regulatory status
The tVNS device is classified as a Class IIa medical device under EU Medical Device Regulation 2017/745 and carries CE marking. It is currently the only non-invasive VNS device with this level of EU-MDR approval.
Approved indications: epilepsy, depression, chronic migraines, and Prader-Willi syndrome.
The device is manufactured by tVNS Technologies GmbH in Germany. Anatomical Concepts (UK) Limited are the exclusive distributors for the UK and Ireland markets.
Quality of evidence considerations
Transparency about the current state of the evidence is important. A systematic review applying the Cochrane Risk of Bias 2.0 tool to 41 randomised controlled trials of tVNS found that only 2 were rated as "low risk" of bias.
The main methodological challenges include:
- Compromised blinding because paresthesia at the stimulation site can effectively unblind participants to their allocation
- Lack of pre-registration of trial protocols, which makes it difficult to assess selective outcome reporting
- Absence of objective biomarkers of neural target engagement, meaning it is currently difficult to confirm that the vagus nerve is being adequately stimulated in individual patients
These limitations do not invalidate the existing evidence, but they do mean that the field would benefit from larger, well-designed confirmatory trials with rigorous blinding protocols. Research is evolving, and parameter standardisation across studies is needed to enable more meaningful meta-analytic comparisons.